Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Paclitaxel 4Cyclophosphamide 4exemestane 3Taxes 3Tamoxifen 3Letrozole 3Doxorubicin 3Anastrozole 3Trastuzumab 2Leuprolide 2Immunotherapy 2Goserelin 2Carboplatin 2trastuzumab biosimilar HLX02 1ribociclib 1pegfilgrastim 1elacestrant 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abemaciclib 1Vitamins 1Standard of Care 1Radiosurgery 1Psychiatric Rehabilitation 1Practice Guidelines as Topic 1PF-05280014 1Ontruzant 1Omeprazole 1Ogivri 1Neoadjuvant Therapy 1Methods 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × Vitamins × 1 year × Clear all
NCT02950259 2025-12-03

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Providence Health & Services

Phase 1 Completed
16 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡